These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1912530)

  • 1. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs.
    Lazo JS; Basu A
    Semin Cancer Biol; 1991 Aug; 2(4):267-71. PubMed ID: 1912530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metallothionein null cells have increased sensitivity to anticancer drugs.
    Kondo Y; Woo ES; Michalska AE; Choo KH; Lazo JS
    Cancer Res; 1995 May; 55(10):2021-3. PubMed ID: 7743495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective function of metallothionein against certain anticancer agents.
    Endresen L; Rugstad HE
    Experientia Suppl; 1987; 52():595-602. PubMed ID: 2959550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein.
    Koropatnick J; Pearson J
    Mol Pharmacol; 1993 Jul; 44(1):44-50. PubMed ID: 8341278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.
    Satoh M; Cherian MG; Imura N; Shimizu H
    Cancer Res; 1994 Oct; 54(20):5255-7. PubMed ID: 7923149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice.
    Okazaki Y; Miura N; Satoh M; Imura N; Naganuma A
    Biochem Biophys Res Commun; 1998 Apr; 245(3):815-8. PubMed ID: 9588197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metallothionein].
    Naganuma A
    Nihon Rinsho; 1997 May; 55(5):1091-5. PubMed ID: 9155158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.
    Yokomizo A; Ono M; Nanri H; Makino Y; Ohga T; Wada M; Okamoto T; Yodoi J; Kuwano M; Kohno K
    Cancer Res; 1995 Oct; 55(19):4293-6. PubMed ID: 7671238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metallothionein as a resistance factor for antitumor drugs].
    Imura N; Naganuma A; Satoh M
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):599-604. PubMed ID: 2705789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.
    Schenk PW; Brok M; Boersma AW; Brandsma JA; Den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
    Mol Pharmacol; 2003 Aug; 64(2):259-68. PubMed ID: 12869630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
    Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
    Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
    Wang W; Liu G; Zheng J
    Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of metallothionein in cancer chemotherapy].
    Naganuma A; Imura N
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of metallothioneins in anticancer drug resistance.
    Bahnson RR; Basu A; Lazo JS
    Cancer Treat Res; 1991; 57():251-60. PubMed ID: 1686720
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs.
    Gupta RS
    Cancer Treat Rep; 1985 May; 69(5):515-21. PubMed ID: 2860971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of metallothionein confers resistance to anticancer drugs.
    Kelley SL; Basu A; Teicher BA; Hacker MP; Hamer DH; Lazo JS
    Science; 1988 Sep; 241(4874):1813-5. PubMed ID: 3175622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 beta-mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum.
    Kondo Y; Kuo SM; Lazo JS
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1313-8. PubMed ID: 7932184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
    Yang X; Pagé M
    Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha(v)beta(3) Integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species.
    Brozovic A; Majhen D; Roje V; Mikac N; Jakopec S; Fritz G; Osmak M; Ambriovic-Ristov A
    Mol Pharmacol; 2008 Jul; 74(1):298-306. PubMed ID: 18441044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.